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Abstract
Background: Guidelines exist for chronic kidney disease (CKD) but are not well implemented in clinical practice.
We evaluated the impact of a guideline-based clinical decision support system (CDSS) on laboratory monitoring
and achievement of laboratory targets in stage 3–4 CKD patients.
Methods: We performed a matched cohort study of 12,353 stage 3–4 CKD patients whose physicians opted to
receive an automated guideline-based CDSS with CKD-related lab results, and 42,996 matched controls whose
physicians did not receive the CDSS. Physicians were from US community-based physician practices utilizing a large,
commercial laboratory (LabCorp®).
We compared the percentage of laboratory tests obtained within guideline-recommended intervals and the
percentage of results within guideline target ranges between CDSS and non-CDSS patients. Laboratory tests
analyzed included estimated glomerular filtration rate, plasma parathyroid hormone, serum calcium, phosphorus,
25-hydroxy vitamin D (25-D), total carbon dioxide, transferrin saturation (TSAT), LDL cholesterol (LDL-C), blood
hemoglobin, and urine protein measurements.
Results: Physicians who used the CDSS ordered all CKD-relevant testing more in accord with guidelines than those
who did not use the system. Odds ratios favoring CDSS ranged from 1.29 (TSAT) to 1.88 (serum phosphorus) [CI,
1.20 to 2.01], p < 0.001 for all tests. The CDSS impact was greater for primary care physicians versus nephrologists.
CDSS physicians met guideline targets for LDL-C and 25-D more often, but hemoglobin targets less often, than
non-CDSS physicians. Use of CDSS did not impact guideline target achievement for the remaining tests.
Conclusions: Use of an automated laboratory-based CDSS may improve physician adherence to guidelines with
respect to timely monitoring of CKD.
Background
Many studies have shown that, as a rule, physicians do
not follow clinical guidelines very well [1–3]. Common
reasons include lack of awareness, familiarity, and agree-
ment, inertia of previous practice, and external barriers
such as the guidelines being inconvenient, confusing, and
cumbersome [1]. These facts have been important in driv-
ing the development of clinical decision support systems
(CDSS) that convey guideline materials to physicians in
ways that are convenient and therefore potentially effect-
ive in altering behavior [4].
However, CDSS have not consistently improved
physician adherence to guidelines concerning proper
and timely test ordering [5–9]. Although some trials
have shown positive results, many of them were con-
ducted within healthcare systems whose structures
helped implement the recommendations [9]. Thus far,
no trials or studies have documented the effects of a
scalable CDSS like the one presented here which de-
pends upon nothing but algorithm-driven advice em-
bedded in aboratory reports and sent to physicians as
part of their routine work flow.
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Because of manifest necessity for achieving proper care
of patients with chronic kidney disease (CKD), extensive
guidelines have been created by the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI™) [10–14] and the Kidney Disease: Improving
Global Outcomes (KDIGO®) Work Groups [15–19].
To-date, few CDSS have attempted to implement them
[20–23]. We present here the results of a matched
cohort study of a CDSS designed to implement the
KDOQI™/KDIGO® guidelines via laboratory-based in-
terpretive reports delivered to community-based phy-
sicians as part of their routine laboratory reporting
from a single national testing vendor. Despite the
absence of any organized research or practice struc-
tures to facilitate adherence to guidelines, we were
able to show an improved alignment between guide-
line recommendations and both test ordering and, in
two instances, test results.
Methods
The CDSS program
The CDSS program is an enhanced laboratory reporting
system serving physicians who use a large commercial
laboratory (Laboratory Corporation of America® Hold-
ings (LabCorp)). KDOQI™ and KDIGO® guidelines con-
cerning kidney function, CKD mineral bone disorder,
anemia, and lipids were translated into a comprehensive
reporting program by some of the authors (FC, JA, EW,
and JE). Guideline translation and adjudication of differ-
ences between guidelines were supervised by a panel of
authorities, many of whom had participated in their
development (Additional file 1). For each of these four
areas, the reporting program interprets an individual
patient’s current laboratory results and changes over
time to produce suggestions for treatment and follow
up testing (Additional file 2). The interpretive text is
part of each laboratory report.
The CDSS program also includes optional flow
sheets of all relevant laboratory results, selected graphs
with trend lines (Additional files 3 and 4), ‘patient
friendly’ explanations of laboratory test results, and
dietary guides for sodium, phosphorus, potassium, and
protein restriction (Additional files 5 and 6).
The LabCorp sales force presented the CDSS pro-
gram to physicians as an optional service at no
additional cost to the patient or physician. “CDSS
physicians” were those who chose to receive any
component of the program offering. “Control physi-
cians” either were not offered CDSS or were offered
it but chose not to receive it. The physicians who
chose to use our CDSS practice practice in 32 US
states. The practices range from solo physicians to
very large multi-specialty groups that use LabCorp
as a laboratory provider.
Study design
We chose a matched cohort study design to control
for potential confounding and selection bias. Western
Institutional Review Board® (Olympia, WA) approved
the study protocol and determined that the study met
requirements for waiver of consent and waiver of
authorization for use and disclosure of protected health
information on August 24, 2012.
We identified 14,524 ‘CDSS patients’ 18 years or older
whose physicians were CDSS physicians and who had at
least two estimated glomerular filtration rate (eGFR)
results between 15 and 59 ml/min/1.73 m2 at least three
months apart (CKD stage 3 or 4). eGFR is calculated
using the CKD-EPI equation and reported with all serum
creatinine measurements at LabCorp. Serum creatinine is
traceable to the isotope dilution mass spectroscopy (IDMS)
standard. Race, used in computing eGFR, was not available
for the overwhelming majority (approximately 96 %) of
patients. When race was unknown, the eGFR calculation
for a non-African American patient was used by default
because the majority of the US population is non-African
American. Physicians received both eGFR calculations as
part of their standard laboratory results report. All patients
had a first laboratory order (accession) between April 2009
and June 2012. The date of the last accession was June
2013. Median follow-up time was 0.73 years. The short
median follow up interval reflects that the majority of pro-
viders were enrolled during 2011–2012.
Non-CDSS patients (‘controls’) were matched in a
four to one ratio when possible on age (± five years),
gender, eGFR (±5 ml/min/1.73 m2), zip code (or state
if zip code was not available), time of the initial
eGFR result of the CDSS patient, and the type of or-
dering physician (primary care, nephrology, or other
specialty). The final analysis dataset consisted of
12,353 CDSS patients and 42,996 matched controls:
9469 CDSS patients with four controls, 678 CDSS
patients with three controls, 880 CDSS patients with
two controls, and 1326 CDSS patients with a single
control. There were 1740 unique CDSS physicians
and 14,402 unique control physicians in the analysis.
The majority of physicians (60 and 81 % of CDSS
and control physicians, respectively) contributed one
to three patients to the study. We could not match
on providers as well as patients because of limited
information concerning provider details.
Definition of study endpoints
We considered 11 analytes: eGFR, plasma parathyroid
hormone (PTH), serum calcium, phosphorus, 25-hydroxy
vitamin D (25-D), total carbon dioxide (CO2), transferrin
saturation (TSAT) in anemic patients, and LDL cholesterol
(LDL-C), blood hemoglobin, and urine panels (urine albu-
min/gram creatinine or urine protein/gram creatinine). For
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each, we compared the fraction of follow-up tests obtained
within the guideline-recommended intervals (Table 1) and
the fraction of values within guideline target ranges
(Table 1) for CDSS and control patients. These were our
primary endpoints.
Criteria for inclusion in the testing frequency analysis
For each analyte, patient inclusion criteria in the testing
interval analysis were based on the adequacy of the
‘follow-up interval’, defined from the first accession that
included an eGFR to the last accession available for that
patient, plus a three month window. The ‘testing inter-
val’ was defined from the first accession to the next test
of that specific analyte. If either the testing interval or
the ‘recommended interval’ (Table 1) was less than the
follow-up interval, the patient was included in the ana-
lysis. After a patient’s last observed accession, we
could not know if that patient would ever be tested
again at LabCorp. As such we assumed patients were
still ‘LabCorp patients’ for up to 3 months following their
last known accession date. We performed a sensitivity
analysis of the ordering results for selected lab tests,
using a 1 month and 6 month assumption on the drop-
out. There was no qualitative difference in the results
when compared to the 3 month assumption. Therefore
only the 3 month results are presented.
In some cases, analytes were not available at the start of
the follow-up interval. For example, PTH may not have
been measured, even though an eGFR result was available.
As a study convention, we assumed the result (PTH, for ex-
ample) was within the target range for the CKD stage; we
compared timing to the next measurement from the
entry point to guideline recommendations assuming
a value within the target range at entry (Table 1).
Criteria for success for the testing frequency analysis
If the testing interval was less than or equal to the rec-
ommended interval, we considered the outcome a suc-
cess. If the testing interval exceeded the recommended
interval, we considered the outcome a failure. In other
words, there was no penalty for over-testing, only
under-testing. We allowed a grace window of 14 days
and 30 days for recommended testing intervals of
3 months and 12 months, respectively.
Criteria for inclusion and success for guideline target
analysis
For the assessment of achieving guideline target lab
values, every relevant analyte in every available accession
was included for each patient. A binary indicator was
created for each lab result. If the lab value fell within the
recommended target range, the observation was considered
a success. Otherwise, the observation was considered a
failure.
Statistical analysis
Logistic regression was used to compare the odds of or-
dering compliance between CDSS and control patients.
Although patients were sometimes followed for multiple
intervals, the current analysis focused on the first rec-
ommended accession following the baseline visit. This
decision was based on the fact that many patients were
not “at risk” for a second accession and because the
study sampling scheme makes it impossible to determine
if an absence without accessions is due to patient drop-
out. Each patient received a binary indicator of compli-
ance as described above. Comparisons of the odds of
compliance between CDSS and control patients were
adjusted for age at entry into the cohort, gender, CKD
stage, and physician specialty using logistic regression.
Parameter estimates were obtained via maximum
likelihood, and corresponding confidence intervals
and p-values were computed using a normal approxi-
mation. To test the hypothesis that the effect of CDSS
involvement on ordering compliance differs by CKD stage
and/or physician specialty, multiplicative interactions
between CDSS and CKD stage/physician specialty were
tested using the likelihood ratio test. Analytic results are
presented using all available patients and are stratified
by CKD stage and physician specialty. Analyses account-
ing for possible correlation within physician revealed no
qualitative change in inference.
Generalized estimating equations with a logit link
function were used to compare the odds of target com-
pliance between CDSS and control practices. Because a
patient could contribute multiple observations (one for
each lab accession), we accounted for within-subject
correlation across measurements using working correl-
ation structures which were chosen using empirical
covariance matrices. Robust variance estimates cluster-
ing on patient were used for inference regarding model
parameters [24]. All analyses were adjusted for age at
entry into the cohort, gender, CKD stage, and phys-
ician specialty. Again, interactions by CDSS status and
CKD stage and physician specialty were considered.
Results
CDSS patients and controls were well balanced across the
majority of baseline characteristics due to the matched
design (Table 2). With one exception, tests of differences
between the two groups were significant at the 0.05 level
simply because of the large sample size available rather
than because of clinically meaningful differences between
the groups. The exception was that CDSS patients were
cared for by a slightly higher proportion of nephrologists
(34.0 vs. 27.4 %) and less primary care physicians (PCPs)
(63.9 vs. 70.2 %) when compared to control patients.
Physicians who used the CDSS ordered all CKD rele-
vant testing more in accord with guidelines than those
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Table 1 Lab measurement frequency and range targets used in the analysis
Lab measurement Frequency Target range
eGFR
-Stage 3 Every 12 months
-Stage 4 Every 3 months
-Stage 5 Every month
PTH
- Stage 3 35 pg/mL to 70 pg/mL
- Previous within target Every 12 months
- Previous outside target Every 3 months
- Stage 4 Every 3 months 70 pg/mL to 110 pg/mL
- Stage 5 Every 3 months 150 pg/mL to 300 pg/mL
Hemoglobin >10 g/dL
- Females
- Previous within 12–17 Every 12 months
- Previous outside 12–17 Every 3 months
- Males
- Previous within 13.5–17 Every 12 months
- Previous outside 13.5–17 Every 3 months
TSAT (hemoglobin below gender specific range) >20 %
- Previous within target Every 12 months
- Previous outside target Every 3 months
25-hydroxyvitamin D > = 30 ng/mL
- Previous within target Every 12 months
- Previous outside target Every 6 months
Serum Ca 8.6 to 10.2 mg/dL
- Stage 3
- Previous within target Every 12 months
- Previous outside target Every 3 months
- Stage 4 Every 3 months
- Stage 5 Every month
Serum Phos 2.7 mg/dL to 4.6 mg/dL
- Stage 3
- Previous within target Every 12 months
- Previous outside target Every 3 months
- Stage 4 Every 3 months
- Stage 5 Every month
LDL Cholesterol <100 mg/dL
- Previous within target Every 12 months
- Previous outside target Every 3 months
CO2 22 to 30 mmol/L
- Stage 3
- Previous within target Every 12 months
- Previous outside target Every 3 months
- Stage 4 Every 3 months
Ennis et al. BMC Nephrology  (2015) 16:163 Page 4 of 11
who did not use the system (Table 3). The increase in
odds for CDSS relative to non-CDSS ranged from 29 %
for TSAT to 88 % for phosphorus. Of interest, the abso-
lute success rates for timely testing were generally not
very high (less than 50 %), except for eGFR, calcium,
CO2, and hemoglobin (Table 3).
The magnitude of the benefit conferred by CDSS was
greater for PCPs than nephrologists for all of the tests
we studied; eGFR, phosphorus, PTH, LDL-C, and urine
panels are illustrated in Figs. 1, 2 and 3. The CDSS ef-
fect was greater among stage 3 compared to stage 4 pa-
tients for eGFR, phosphorus, and PTH (Figs. 1 and 2),
as well as for calcium, CO2, and TSAT (not illustrated).
CDSS physicians met guideline targets for LDL-C and
25-D more often than control physicians (Fig. 4). The
CDSS effect did not differ by CKD stage or physician
specialty (Fig. 4). By contrast, CDSS physicians met
hemoglobin targets less often than control physicians
(Table 4). CDSS did not affect the achievement of the
remaining guideline targets (Table 4).
Discussion
Guidelines for testing frequency
Compared to non-CDSS physicians, CDSS physicians
adhered better to guidelines that concern timely order-
ing of CKD laboratory testing. To the extent that the
guidelines are themselves valid and useful for better-
ment of patient care, these results speak to a corre-
sponding benefit of the CDSS. Being merely an addition
to an otherwise conventional laboratory report, our
CDSS enters practices through conventional workflow por-
tals, imposes no specific burdens of its own, and is scalable
to whatever population size one desires to reach.
Table 1 Lab measurement frequency and range targets used in the analysis (Continued)
- Stage 5 Every month
Urine Albumin/Creatininea 0 to 29 mg/g
- Previous within target Every 12 months
- Previous outside target Every 3 months
Urine Protein/Creatininea 0 to 200 mg/g
- Previous within target Every 12 months
- Previous outside target Every 3 months
aMeasurement of urine albumin/creatinine or urine protein/creatinine ratio satisfies frequency of urine panel
Table 2 Baseline patient characteristics
Baseline characteristic Controls (N = 42,996) CDSS patients (N = 12,353) p-value
Baseline Age (yrs) 76.09 (11.51) 73.03 (11.51) <.001
Gender
- Female 24673 (57.4 %) 7074 (57.3 %) 0.822
- Male 18323 (42.6 %) 5279 (42.7 %)
Race
- White-Caucasian 1628 (3.8 %) 491 (4 %) 0.865
- African-American 799 (1.9 %) 242 (2 %)
- Asian 35 (0.1 %) 11 (0.1 %)
- Hispanic 41 (0.1 %) 12 (0.1 %)
- Other 16 (0 %) 6 (0 %)
- Missing 40477 (94.1 %) 11591 (93.8 %)
Baseline eGFR 41.95 (11.36) 41.51 (11.41) <.001
- 15–29 7198 (16.7 %) 2195 (17.9 %)
- 30–44 15883 (36.9 %) 4559 (37.1 %)
- 45–59 19915 (46.3 %) 5525 (45 %)
Physician Specialty
- Primary Care 30173 (70.2 %) 7896 (63.9 %) <.001
- Nephrology 11802 (27.4 %) 4198 (34 %)
- Other 1021 (2.4 %) 259 (2.1 %)
For Baseline Age and Baseline eGFR, numbers are means (standard deviations). For all other characteristics, numbers are N (%)
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Our data underscore the importance of improving
CKD care because, even with CDSS, no more than
half of laboratory orders were consistent with guide-
line recommendations, except for eGFR, calcium,
CO2, and hemoglobin. Three of these four excep-
tions, eGFR, calcium, and CO2, are part of the most
widely ordered test panels. The low accordance with
guidelines (under-testing) for the remaining tests was
true even among nephrologists. We did not penalize
for over-testing because many of these tests are rou-
tinely ordered for clinical indications outside of CKD
monitoring and we had no means to discern this.
We assumed that missing values in the initial accession
were within the target range for the CKD stage. This
assumption gave all physicians the maximum interval to
the next order and, therefore, imposed the least stringency
in selection of the proper time for re-testing. For example,
if the initial accession for a stage 3 CKD patient did not
Table 3 Estimated odds ratio for ordering laboratory tests within guideline-recommended intervals: CDSS vs Controls
Test Group N N (%) in compliance OR (CI)a p-value
eGFR CDSS 7518 6664 (89) 1.59 (1.45, 1.74) <0.001
Control 18979 15462 (81)
PTH CDSS 8030 2106 (26) 1.68 (1.57, 1.80) <0.001
Control 20121 3405 (17)
25-D CDSS 7630 3638 (48) 1.60 (1.51, 1.69) <0.001
Control 17132 5942 (35)
Calcium CDSS 8335 7076 (85) 1.65 (1.54, 1.77) <0.001
Control 20718 15683 (76)
Phosphorus CDSS 7653 3096 (41) 1.88 (1.76, 2.01) <0.001
Control 19247 5129 (27)
CO2 CDSS 9173 7475 (82) 1.87 (1.75, 1.98) <0.001
Control 23089 16158 (70)
Hemoglobin CDSS 9290 6163 (66) 1.82 (1.73, 1.92) <0.001
Control 22500 11593 (52)
TSAT CDSS 9270 1321 (14) 1.29 (1.20, 1.39) <0.001
Control 22414 2540 (11)
LDL-C CDSS 8017 4488 (56) 1.79 (1.70, 1.89) <0.001
Control 18640 7776 (42)
Urine panel CDSS 6985 2265 (32) 1.56 (1.46, 1.67) <0.001
Control 15874 3525 (22)
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eGFR
Fig. 1 Effect of CDSS on adherence to guideline testing intervals for eGFR. ‘% Success’ refers to percentage of patients with test ordered
within the guideline-recommended time interval. Odds ratios greater than one favor CDSS. PC = primary care, Neph = nephrology, N = number
of patients, OR = odds ratio
Ennis et al. BMC Nephrology  (2015) 16:163 Page 6 of 11
include a PTH, we assumed the PTH was within goal and
allowed a testing interval of one year versus the shorter
interval– 3 months –recommended for an abnormal
PTH. This greater leniency unselectively advantaged all
physicians and diluted the CDSS effect.
As expected, the benefits of CDSS were more marked
for PCPs than nephrologists. The latter have special
training and experience in CKD management, have been
the target of guideline material through journals and sci-
entific meetings, and would be expected to need less
help than PCPs in managing CKD patients. The effect
among nephrologists validates the idea that the program
can improve the performance of even specialists.
Guidelines for laboratory targets
CDSS physicians achieved better laboratory outcomes for
two measurements: LDL-C and 25-D. Our CDSS aims
toward lower LDL-C levels than usual because CKD is a
very high risk state for cardiovascular disease (CVD) [25].
Likewise, 25-D deficiency is common in CKD and a major
contributor to secondary hyperparathyroidism [26, 27].
Advice in these areas for more aggressive LDL-C lowering
and 25-D repletion may have been a stimulus to more
intensive medical care. The benefit of CDSS was similar
across CKD stage and for all physician specialties. Of note,
the KDOQI intact PTH targets used in this analysis are
opinion-based [12] and no longer endorsed by more
recent KDIGO guidelines [17]; this could have contributed
to the lack of achievement of PTH targets in this study.
Since completion of this study, the PTH goals promul-
gated in this CDSS have been updated to reflect the
KDIGO guidelines. It may be that future CDSS studies
using more widely accepted guidelines would demonstrate
a higher rate of compliance.
Strengths and limitations of the study
There are several strengths to this study, such as the large
sample size, the wide geographic distribution, and the
range of practice sizes and specialties. It is true that, as
this was not a randomized controlled trial (RCT), timely
ordering and better achievement of targets could be at-
tributed to chance association. On the other hand, an
RCT concerning physician behavior imposes stringencies
that limit generalizability. Physicians who volunteer to
participate in an RCT may not represent the majority of
physicians in practice. The uniform records and research
coordinators required by RCTs distort the process of clin-
ical care. Our study occurred during the natural course of
medical practice by the very physicians who are the target
audience of the guidelines: those caring for CKD patients.
The brevity of this study (median follow up 0.73 years)
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(a) Serum Phosphorus 
(b) Plasma PTH
Fig. 2 Effect of CDSS on adherence to guideline testing intervals for phosphorus (a) and PTH (b). ‘% Success’ refers to percentage of
patients with test ordered within the guideline-recommended time interval. Odds ratios greater than one favor CDSS. PC = primary care,
Neph = nephrology, N = number of patients, OR = odds ratio
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Estimated Odds Ratio(b) 25-hydroxyvitamin D
Fig. 4 Effect of CDSS on achievement of guideline targets for LDL cholesterol (a) and 25-D (b). ‘% Success’ refers to percentage of patients whose
test result met the guideline recommended target. Odds ratios greater than one favor CDSS. PC = primary care, Neph = nephrology, N = number
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Estimated Odds Ratio
(b) Urine Panels
Fig. 3 Effect of CDSS on adherence to guideline testing intervals for LDL-C (a) and Urine Panels (b). ‘% Success’ refers to percentage of patients
with test ordered within the guideline-recommended time interval. Odds ratios greater than one favor CDSS. The interaction between CDSS and
both CKD stage and physician type was significant (p < 0.001), meaning that the benefits conferred by CDSS varied with CKD stage and physician
type. PC = primary care, Neph = nephrology, N = number of patients, OR = odds ratio
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impact the CDSS program might have on crucial issues
such as CKD progression. If the guidelines are helpful in
reducing the rate of GFR decline, and if our program is
likewise effective in implementing them over the time
intervals needed to assess CKD progression, then our
program might be a means for maintaining kidney func-
tion. These uncertainties point to the need for a longer
study. Additionally, ethnicity was not known for most of
our patients, so matching was imperfect in this respect.
The default use of the non-African American eGFR cal-
culation when race was unknown would tend to under-
estimate GFR and consequently over-diagnose CKD in
African American patients. Because the CDSS did not
‘know’ the correct eGFR to use and physicians did know,
the performance of CDSS in relation to guidelines would
be reduced compared to control physicians whenever
eGFR was critical in the decision making.
Due to the way in which the program was proliferated,
we were unable to determine what proportion of pro-
viders were approached, agreed to receive the CDSS, or
refused the program. Likewise, we cannot provide infor-
mation about provider characteristics such as age years
since training, size of practices, or LabCorp market
share in the given practice locale. We also lack data con-
cerning comorbidities, socioeconomic status and insur-
ance status for the patients. However provider zip code
was used as a surrogate for socioeconomic status. In
addition, because patients were in various stages of CKD
and therefore varied in testing recommendations, each
analyte analysis represents that subset of patients due
for testing. Finally, certain unavoidable biases are inevit-
able. Patients with elevated values are likely to have
more frequent rechecks than those with goal values. Pa-
tients with multiple results may well have more complex
and therapeutically recalcitrant disease. The potential
use of outside labs by a provider may have occurred but
seems equally likely in either group.
The providers themselves are surely a source of selec-
tion bias. Those more interested may well have chosen
to use CDSS. On the other hand, many of the physicians
in the control group were not made aware of our CDSS
program by the LabCorp sales force. This problem can-
not be resolved within the present data set. We cannot
assess provider performance in CKD care prior to our
study because LabCorp did not keep a patient-centered
database at that time.
Prior studies of CDSS
CKD CDSS
Manns et al. studied 93 primary care practices in Canada
treating 22,092 patients with diabetes or proteinuria
[21]. Practices were randomized to receive either an
enhanced eGFR prompt containing suggestions about
ACEi or ARB use, blood pressure control, lipid control,
and A1c target, or a standard eGFR prompt. Although
the primary outcome, which concerned use of ACEi/
Table 4 Estimated odds ratio for achieving guideline-recommended laboratory test targets: CDSS vs Controls
Test Group N N (%) in compliance OR (CI)a p-value
PTH CDSS 12835 4918 (38) 0.99 (0.93, 1.06) 0.851
Control 23582 9062 (38)
25-D CDSS 16910 9332 (55) 1.18 (1.12, 1.25) <0.001
Control 32903 17362 (53)
Calcium CDSS 67222 59847 (89) 1.05 (0.99, 1.10) 0.113
Control 167026 148877 (89)
Phosphorus CDSS 17764 15456 (87) 1.08 (0.99, 1.06) 0.069
Control 29011 24605 (85)
CO2 CDSS 167237 120910 (72) 0.99 (0.96, 1.03) 0.657
Control 68208 47701 (70)
Hemoglobin CDSS 47740 18528 (39) 0.92 (0.88, 0.97) 0.001
Control 45229 108476 (42)
TSAT CDSS 8119 5495 (68) 0.98 (0.90, 1.07) 0.699
Control 15717 10716 (68)
LDL-C CDSS 25278 17232 (68) 1.16 (1.10, 1.22) <0.001
Control 63738 41957 (66)
Urine panel CDSS 8806 4263 (48) 0.94 (0.87, 1.02) 0.156
Control 25814 12877 (50)
aValues are estimated odds ratios for meeting guideline target values of CKD relevant laboratory measurements after adjustment for age at entry into the cohort,
gender, CKD stage, and physician specialty
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ARB, was limited to the 5444 patients over age 65 for
whom data were available, the results that concern
laboratory testing were based upon all patients. They
found the prompt improved the rate of urine albumin
measurements, but not that of LDL-C or HbA1c mea-
surements. The enhanced prompt did not alter the
achievement of laboratory test targets.
In another study [20], real-time automated alerts
recommending nephrology referral and urine albumin
measurements failed to significantly improve either
endpoint. Studies of CDSS aimed at reducing adverse
drug events or renal function impairment in CKD
patients have shown benefits only in reducing medica-
tion errors [28, 29].
All in all, the record of CDSS usage for CKD has
not been such as to promote its widespread adoption.
By contrast, our CDSS might have practical value. It
is scalable, and imposes no extra effort on physicians
or their support staff. Our CDSS is specific to an
individual patient and cognizant of changes over time.
At the very least, it appears to improve the timeliness
of lab test ordering. It may, in some cases, lead to
better achievement of laboratory targets.
Non-CKD CDSS
Our results are in line with or perhaps more promising
than those from non-CKD trials of CDSS. Bright et al.
reviewed 148 RCTs of CDSS [9]. Of these, 128 were
health care process trials like ours. Overall, CDSS
improved ordering of clinical studies that included labora-
tory testing and procedures, preventative care services,
and treatments. The overall odds ratio averaged 1.72,
similar to the present study. CDSS tended to improve
morbidity outcomes such as hospitalizations, cardio-
vascular events, DVTs, and infections. Mortality was
not affected. Studies of cost-effectiveness were not
consistent. All in all, the general results for this
meta-analysis are in reasonable accord with our own
results, even though ours was not an RCT. Only 20
of the studies in this meta-analysis dealt with lab test
ordering. Almost none were national in scope like
ours; most were performed at one or a few sites,
except for a large study at Kaiser Permanente [30].
Three studies published subsequent to Bright et al.
found somewhat more negative results. A meta-analysis of
15 diabetes management trials concluded that CDSS did
not improve practitioner performance or patient out-
comes [5]. Eaton et al. performed a cluster RCT to evalu-
ate a CDSS for improving adherence to cholesterol
guidelines in 30 New England primary care practices and
found no significant differences in lipid screening or
achievement of cholesterol goals [6]. Anchala et al. evalu-
ated ten RCTs and observational studies of CDSS in blood
pressure management and CVD prevention [31]. Pooled
results for reduction of systolic blood pressure were not
significant. Although individual studies suggested mod-
est improvements in outcomes such as reductions in
acute myocardial infarction and cardiovascular re-
hospitalization, data were too sparse to demonstrate a
definitive benefit of CDSS for CVD prevention.
Roshanov et al. reviewed 162 RCTs concerning what
factors associated with success or failure of CDSS [32].
They found that 58 % of RCTs showed some benefit of
clinical process or patient outcomes. CDSS that pro-
vided advice for patients as well as physicians, required
a reason for overriding the CDSS, or were tested by the
CDSS creators showed better results. Systems that pre-
sented advice within electronic health records or order
entry systems were less likely to be effective. Our CDSS
possesses several of the characteristics associated with
success: providing advice for patients and physicians,
testing by the creators, and delivery outside the elec-
tronic health record and ordering system.
Conclusions
Our study illustrates that a national laboratory is a platform
of sufficient scalability to deliver CDSS programs to physi-
cians throughout the country via their natural workflow
portals and thereby transmit guidelines to their intended
audiences. This CDSS seems a promising tool to improve
guideline-based laboratory test ordering and perhaps out-
comes in CKD. We believe it is the first to be reported by a
national laboratory. That large scale systems can deliver
guidelines into practices, and thereby affect the behavior of
large numbers of physicians, means that guideline authors
may well acquire increasing influence and a correspond-
ingly greater responsibility.
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